Not necessarily, and CytoDyn states that they were going through the proper CFDA channels, so it seems they may be doing similar with the exception that China hasn’t stated that they will manufacture leronlimab.

“BrightGene said that before selling the drug, it will have to license it from Gilead, conduct clinical trials and obtain approval. Its technology to make remdesivir may not be of much value if the drug fails to produce results from clinical trials, or if the epidemic comes under control soon, it said.”